减肥神药帝国的下一步扩张,礼来斥资13亿美元押注基因编辑。6月16日,据媒体报道,全球最大制药巨头礼来公司正准备以高达13亿美元的价格收购基因编辑初创公司Verve Therapeutics,其中10亿美元为预付款,另外3亿美元将根据Verve达成特定临床里程碑支付。对于Verve而言,这无疑是一笔极具吸引力的交易。截至周一收盘,这家位于波士顿的生物技术公司市值仅为5.59亿美元,礼来的报价几乎是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.